Background: Worldwide,~69 million people per year sustain a traumatic brain injury (TBI); many develop post-traumatic headache (PTH). There has been little study of treatments for mild TBI (mTBI) or PTH, and clinicians often use drugs approved for primary headache disorders. Many patients self-treat with OTC agents or NSAIDs but have suboptimal pain relief. We initiated a randomised, double-blind (DB), sham-controlled, parallel-group pilot study of non-invasive vagus nerve stimulation (nVNS) for acute and preventive treatment of PTH. Methods: The study is enrolling adults who present 1-4 wks after a head injury, meet ICHD-3 criteria for acute headache attributed to mTBI, and have ≥2 headaches/wk with a migraine or probable migraine phenotype. After a 2-wk run-in period, subjects will be randomly assigned (1:1 allocation) to receive daily preventive therapy and as-needed acute treatment with nVNS or a sham device. Preventive therapy will consist of two 120-second stimulations given 3 times daily. Acute treatment will comprise 2 stimulations administered at headache onset, followed by 2 stimulations given 20 min after the start of initial treatment. Subjects are not to use acute rescue medication for 120 min post-treatment. The primary effectiveness endpoint is the decrease in pain (on a 7-point numeric scale) at 60 min post-treatment for all treated headache attacks. Secondary endpoints include decrease in the frequency of headache days between the run-in period and the last 2 wks of the DB period and responder rates (ie, percentages of subjects with ≥50% decrease in attack frequency). The primary safety endpoint is the incidence of treatment-related serious adverse events. Results: Up to 80 subjects will be enrolled at 1 North American site. The expected duration is 12 mos (9 mos for enrolment, 14 wks for active participation). Discussion: This study is designed to assess the efficacy and safety of nVNS as a novel acute and preventive therapy for PTH. Author Disclosures B. Vargas has received advisory board fees from Amgen, Novartis, Allergan, Alder, Teva, Lilly, Upsher-Smith, Biohaven, Promius, and Xoc and has received speaker fees from ATI. He serves on the board of directors for the American Headache Society and the Headache Cooperative of the Pacific and is an editorial board member for Neurology Today. E. Liebler is an employee of electroCore, Inc., and receives stock ownership. S. Bunt has no financial conflicts of interest to declare. C. Supnet has no financial conflicts of interest to declare.
Background
About 40 to 50% of migraine patients have a comorbid depression. However, there is no evidence-based medicine for treating depressive symptoms in depressed migraine patients. We identified factors reducing depressive symptoms in these patients.
Methods
We reviewed electronic data which collected new patients with migraine in our headache clinic. A total of 604 patients were found. Among them, we included patients who had depression at an initial visit (T1) and who could be followed at 12 weeks (T2). All patients conducted the Patient Health Questionnaire-9 (PHQ-9) at two periods. We stipulated that 8 or more of the PHQ-9 score suggest depression. We examined factors to be associated with the decrement of the PHQ-9 score during 12 weeks. Results A total of 502 patients were excluded in the review due to having no depression (n=398) at T1 and no visit at T2 (n=104). Finally, 102 depressed patients were included in the study. Of them, 24 patients (23.5%) had medication overuse headache (MOH) and 36 (35.3%) received psychiatric drugs including antidepressants and anxiolytics. All took preventive drugs at T2. Mean score of the PHQ-9 at T1 was significantly decreased at T2 (p < 0.001). Mean difference of the PHQ-9 score was correlated with MOH and mean differences of attack frequency, headache day, and the VAS score by univariate analyses. However, the type of preventive drugs and the intake of psychiatric drugs were not associated. The strongest factor by multivariate analyses was mean difference of headache day (ß = 0.345, p < 0.001) followed by MOH (ß = 0.249, p = 0.008).
Discussion
The improvement of depressive symptoms in depressed migraine patients may rely on the headache management instead of the use of psychiatric drugs.
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AHS Abstract: The association between occurrence of migraine headache and objectively-assessed sleep among adults with episodic migraine: A Prospective Cohort Study Angeliki Vgontzas 1, 3 , Wenyuan Li 2,4 , Elizabeth Mostofsky 4 , Murray A. Mittleman 2, 3, 4 , Suzanne Bertisch 1, 2, 3 studies have been limited to individuals without headache. Our aim was to assess whether self-reported sleep characteristics in those with migraine and TTH in a population-based sample were associated with increased pain sensitivity. Methods: A sample of 644 adult individuals underwent a headache interview (using ICHD criteria) and completed a questionnaire that included four items on sleep (self-reported duration, sleeping problem, snoring and feeling well-rested). A total of 314 participants also underwent concurrent pain testing, including a pericranial total tenderness score (TTS), and cephalic and extracephalic pressure pain thresholds (PPTs). Data were analyzed using adjusted logistic or linear regression. Results: The sample was comprised of 40.9% headache sufferers (22.8% migraine, 17.1% TTH), of whom 12.5% had chronic headache (CH). Compared to non-headache sufferers, those with headache were more likely to report a sleep problem [OR=2.8(1.7-4.5)] and not feeling well-rested [OR=3.0(2.1-4.4)]. There was no difference in average sleep duration or snoring. TTS, but not PPTs, was higher in those with sleep problems and this difference was greater for CH (26.7, p= 0.014) than for EH (19.1, p=0.051) compared to controls (14.0, ref). Similar results were found for those not well rested, with a higher TTS in those with CH (25.3, p<0.001) and EH (19.5, p=0.015) compared to controls (12.0, ref). Conclusion: Migraine and TTH are associated with higher rates of self-reported sleep problems and feeling unrested. TTS indicates increased pain sensitivity among those who report more sleep problems and this difference is greater for those with CH. Causal sequence cannot be determined in cross-sectional data. Future work is needed to determine if disturbed sleep modifies pericranial tenderness contributing to overall headache burden. Background: It is commonly accepted that larger pain extent reflects a clinical sign of central sensitization and enlarged areas of pain have been associated with more severe pain and greater pressure pain sensitivity in some musculoskeletal pain conditions, e.g., knee osteoarthritis or whiplash associated neck pain. However, this association has not been observed in primary headaches such as tension-type headache or migraine. The aim of this study was to investigate whether the perceived pain extent, as assessed from self-reported pain drawings, relates to widespread pressure pain sensitivity, clinical pain and psychological outcomes in men with cluster headache. Methods: Forty men with episodic cluster headache reported their pain on four different body charts representing the head/neck which were subsequently digitized allowing pain extent to be calculated utilising a novel software. Pressure pain thresholds (PPT) were assessed bilaterally over the temporalis muscle (trigeminal area), C5-C6 joint (extra-trigeminal area) and tibialis anterior muscle (distant pain-free area). Clinical features (cluster periods/year; number of attacks/day, pain intensity) of the headache, and anxiety/depressive levels (Hospital Anxiety-Depression Scale, HADS) were also assessed. Pearson correlation coefficients were computed to reveal correlations between pain extent and the remaining outcomes. Results: No significant associations between pain extent and PPTs in trigeminal, extra-trigeminal and distant pain-free areas, headache features, and psychological variables, e.g., anxiety/depressive levels were found. Conclusions: Pain extent in the trigemino-cervical area was not associated with any of the clinical outcomes and not related to the degree of pressure pain sensitization in men with episodic cluster headache.
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Pain Extent is not Related to Widespread Pressure Pain Sensitivity in Men with Episodic Cluster Headache
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Central sensitization in Men with Episodic Cluster Headache García-Azorín D 1 , Palacios-Ceña M 2 , Gómez-Mayordomo V 3 , FuensalidaNovo S 2 , González-García N 3 , Guerrero AL 1 , Cuadrado ML 3 , Fernández-de-las-Peñas C Background: It is claimed that central sensitization can also play, in conjunction with vascular processes, a relevant role in the pathogenesis of cluster headache. Widespread pressure pain hypersensitivity is a clinical manifestation of sensitization of central pain pathways which has been observed in other primary headaches such as migraine or tension type headache. The aim of this study was to investigate the presence of pressure pain sensitivity within trigeminal (symptomatic) and extra-trigeminal (pain-free) areas in a sample of men with episodic cluster headache. Methods: Forty men with episodic cluster headache and 40 matched controls participated. Pressure pain thresholds (PPT) were bilaterally assessed over one trigeminal point (i.e., temporalis muscle), one extra-trigeminal points (i.e., C5/C6 joint), and two distant points (i.e., second metacarpal and tibialis anterior muscle) by an assessor blinded to the subject's condition. Patients were assessed in a remission phase, at least 1 month from the last cluster attack and without taking preventive medication. Results: The analysis found that PPTs were significantly decreased bilaterally over the trigeminal (mean difference: 85-93 kPa), extra-trigeminal (62-79 kPa), and distant (second metacarpal: 72-92 kPa; tibialis anterior: 135-155 kPa) points in men with cluster headache when compared to healthy controls (all, P<0.001). No significant association between widespread PPTs and clinical headache features was found. Conclusions: Our findings revealed bilateral widespread sensitivity to pressure pain in men with episodic cluster headache during a remission phase. These results support the presence of sensitization of central pathways in episodic cluster headache although individuals were asymptomatic (remission phase) and without medication.
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Observational, open-label, non-randomized study on the efficacy of onabotulinumtoxinA in the treatment of Nummular Headache: Series of 38 patients: García-Azorín D, Sierra A, Trigo J, Martínez-Pías E, Guerrero Al BACKGROUND Nummular headache (NH) is a primary headache representing around 4% of patients in hospital-based series 1 . Neuromodulators or antidepressants are the most used preventives 2 . Small fiber impairment has been described 2 , which represents a potential target for onabotulinumtoxinA (OnabotA) 3 . We aimed to evaluate efficacy of OnabotA in the treatment of NH.
METHODS Observational, open-label, non-randomized, study. We included patients older than 18 with IHCD diagnosis of NH, with at least 10 headache days per month. 
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A particular case of facial paraesthesias due to a meningioma Angelo Torrente
, Concetta Rubino
Objective: here we aim to show a case of facial paraesthesias due to the uncommon cause of a meningioma. Case study: a 63-years-old-woman came to our outpatient neurological clinic for the gradual onset of paraesthesias to the left half of the superior lip in three months. Her complaint started as a tingling sensation and became progressively more and more intense until turning into a burning and swelling sensation. The sensations were constant, worsened by speaking and reduced during the night. We first prescribed a medical therapy (pregabalin and a supplement drug containing vitamins B1, B6, E and α-lipoic acid). After, the patient underwent a massive facial MR and, later, a brain contrast enhanced (CE) MR. Finally, she underwent a neurosurgical consult, a radiotherapic one and cyberknife intervention. Results: neurological examination was irrelevant, symptoms decreased just a little after medical therapy. The basic massive facial MR showed only an intrasellar arachnoidocele. The following brain CEMR showed an extracranial vascularised formation at the level of left cerebellopontine angle (coronal diameter 13x12mm, axial one 16.7x16.4mm), with marked dural contrast enhancement and associated to compression of the origin of left trigeminal nerve and Gasser's ganglion. Neurosurgeon suggested to consult a radiotherapist, who set two options: watchful waiting or performing cyberknife intervention; our patient chose the latter option (25Gy in 5 fractions) with a reduction of symptoms (no more swelling sensation and no speech worsening), but persistence of paraesthesias. Discussion: cerebellopontine angle tumours may cause trigeminal neuralgia, but such painful condition is usually brief, intense and electric shock-like. In our case, the meningioma is probably the cause of such particular clinical presentation and cyberknife intervention may have reduced tumour dimensions, soothing symptoms. Since patient did not recovered fully, other approaches are still needed. Note: authors of this abstract have nothing to disclose. Written, informed consent for publication was obtained from the patient. ABSTRACT Aim: To assess cognitive functions in migraine patients (with and without aura) in comparison to a healthy control group. Method: The research sample is divided in two groups: the research group, which consists of 31 migraine patients (10 of them having migraine aura) that fulfill the diagnostic criteria of the ICHD-3 beta version, and the control group, which consists of 30 healthy subjects, matched by age and education years. In this research design, neuropsychological tests are used for the assessment of cognitive functions, while scales and questionnaires are used for the collection of demographic and clinical data. Results: Statistical analyses show that the performance of migraineurs and especially of those without aura in interictal stages is significant lower than the group of healthy subjects in the tasks of Immediate, Delayed Recall and Memory Recognition of the Rey Complex Figure Test (RCFT) and MoCA. In contrast, they score higher than healthy controls in the Beck Depression Inventory (BDI). However, after controlling for the effect of MoCA on the results no main effect of migraine aura is found. Conclusions: In interictal stages migraineurs and especially migraineurs without aura exhibit significant lower performance scores compared to a group of healthy controls in neuropsychological tests of visual memory recall and recognition. Chief at the Neurology Department of "G.Gennimatas"General Hospital of Athens; Backround: Migraine is a highly disabling disease, usually accompanied by medication overuse with high financial and social impact. Neuromodulation may play an important role in the application of new alternative treatment with microcautery stimulation on sites of cutaneous allodynia for these patients. The present study is based on the theory of the distorted communication within trigeminocervical complex. Objectives: The aim of this study was to evaluate the efficacy of micro-cautery stimulation on patients with chronic migraine -with and without aura-and MOH Materials and methods: A total of 21 patients with migraine were selected. All of them were chronic migraneurs with poor response to medication. The cauterisation on cervical, occipital and temporal areas, depending on what the patients referred to as the most painful points during the attack of migraine and also during the interictal period, once a week for about 4 months. Results: An evaluation scale was completed at the end of the study for each individual. The majority reported a significant amelioration, in frequency, intensity, duration in pain and a decrease in the use of medication. To be noted that several patients continued the sessions after the end of the study. Conclusion: It seems that the thermal micro-cauterisation may be very useful to assist patients with migraine. Possible mechanisms underlying the effectiveness of the method are discussed. OBJECTIVE: Primary headaches, especially migraine, are disorders with an important impact on public health. Migraine is at the seventh place among the more disabling disorders. It is very important for specialists to have an adequate training for the management of headaches. The increasing development of social networks and in general of digital instruments led us to implement our project of a digital platform only focused on headaches, started in 2014 with the technological support of an industrial sponsor (Janssen). We monitored the activity of the platform in the following years, publishing some works (1-3) that emphasized its strengths and weaknesses. The aim of the current study is to analyze strengths and limits of a digital platform in headache training after 5 years. METHODS: Our platform is totally free and easily accessible to doctors after registration and approval of the group's administrators. It is possible to access using website or smartphone app. It is divided in a section for pediatric and a section for adult headaches and contains more than 270 resources totally concerning headache. Each member can download or upload contents and discuss clinical cases. Users can choose to receive notifications for each new contribution via email. We have also created a WhatsApp group to alert members about new contributions and to encourage real-time communication.
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Digital therapeutics neuromodulation for migraine
Administrators can follow the members' activity (number of access, trend topics, uploaded/downloaded resources, discussions, average download for user). We monitored the evolution of the platform's activities over time and compared our experience with other digital platforms. RESULTS: To this day the section dedicated to adult headaches includes 60 members and each did 14 downloads on average. The section dedicated to pediatric headaches includes 67 members with average of 19 downloads. We highlighted a progressive increase in the number of users since the start of our project and an increase in the number of downloads simultaneously with upload of new resources. The items that most capture the attention are PowerPoint presentations and resources closely related to common clinical cases or with short reading time. Below the top ten of the downloaded articles:
Resource Downloads
Headache treatment PowerPoint 72
Article: When to investigate headache 69
Master in headache PowerPoint 48
Migraine aura videos 37
Innovation in migraine 36
Continuum neurology 36
Dysphagia and neuromuscular disease PowerPoint 31
Secondary headaches PowerPoint 29
Group IV headaches (according to ICHD III) PwP 23
Secondary headaches algorithm 22
The data collected during this monitoring period also showed that the number of uploads remains low and appears considerable the difference with the number of downloads. Most of the resources were uploaded mainly by the administrator (about 90%) and by a few other users (5 users). In general there are few discussed cases and the activity of the platform members appears to be considerably reduced during the summer months. Even the Whatsapp group has not significantly increased the number of active members. Finally, there is not a great difference in activity between specialists enrolled in a scientific society dedicated to headaches and those enrolled in other societies (neurologists, childhood neuropsychiatrists). Some of these data are quickly summarized in the following chart, in which the blue dot indicates the total number of downloads and the red dot indicates the total number of uploads in that month: CONCLUSIONS: The increase in subscriptions shows that our social network dedicated to headaches is appreciated by the scientific community. Nevertheless, the activity does not appear equally increased (same average of downloads and uploads per member during these years, a slight increase in the number of active members) and a considerable number of members very rarely access the platform. We observed a paradoxical contrast between the increasing interest on this instrument (exponential increase of subscription to platform for headaches) and its consequent poor use by the registered specialists. There is no difference in its use between headache specialists and other specialists. Furthermore, on average the number of uploads is remarkably lower than downloads, indicating passive use of the platform.
In the other platforms, discussions and downloads are considerably less than the number of subscribers, similarly to the activity of our platform. These results confirm the potential but also the limits of digital instruments in the training for specialists, both in headaches and in other disorders. In order to improve the functionality of our platform, a total renewal of the graphic interface is already in place, which will make it even easier and more pleasant to use. Future perspectives could be the use of typical tools of social networks such as the possibility of writing posts even without uploading content and adding reactions to the interventions of other users, the creation of a chat that allows Placebo is the therapeutic response after the administration of a pharmacologically inactive agent. Its negative equivalent, nocebo refers to the development of adverse events (AEs) from the administration of an inert substance and it is very prevalent among treatments for neurological disorders, resulting in low adherence and poor treatment outcome. Objective: To estimate the incidence of placebo and the incidence and severity of nocebo responses in clinical trials of monoclonal antibodies against the calcitonin gene-related peptide (CGRP) pathway for episodic (EM) and chronic migraine (CM) and compare them to those of topiramate and onabotulinum toxin A as standard treatments for EM and CM, respectively. Methods: We conducted a systematic Pubmed and clinicaltrials.gov search for all randomised, placebo controlled, phase 3 trials of anti-CGRP monoclonals, topiramate and onabotulinum toxin A. A meta analysis of the frequency of placebo effect was performed by pooling the percentage of placebo-treated patients who had at least 50% reduction from baseline in migraine days per month. Meta-analysis of the incidence of nocebo responses was performed by pooling the percentage of placebo-treated patients that exhibited any adverse event. Nocebo severity was calculated from the percentage of placebo-treated patients that exhibited any serious adverse events (SAE) and the percentage of placebo-treated patients that droppedout due to AEs.
Results:
The pooled estimate for placebo frequency was 30% (95% CI: 24.1 -36) in EM trials and 24.1% (95% CI: 11.1 -37.2) in CM trials of anti-CGRP monoclonal, whereas the pooled placebo frequency in topiramate trials in EM was estimated to be 24.2% (95% CI: 19.5 -28.8).
The pooled estimate of incidence of nocebo responses was 59.6% (95% CI: 57.2 -62) in anti-CGRP trials for EM. The pooled serious nocebo responses and the pooled estimate of drop-outs due to nocebo were 1.5% (95% CI: 1.0 -2.0) and 1.5% (95% CI: 0.7 -2.2), respectively in anti CGRP trials for EM. On the other hand, the pooled incidence of dropouts due to nocebo in topiramate trials in EM was 9.2% (95% CI: 7 -11.5). The pooled estimate of incidence of nocebo responses in CM trials of anti-CGRP agents was 51.1% (95% CI: 37.9 -64.4) and the pooled serious nocebo responses and the pooled estimate of drop-outs due to nocebo were 0.9% (95% CI: 0.4 -1.4) and 1.1% (95% CI: 0.3 -1.8), respectively. In onabotulinum toxin A trials in CM, the overall nocebo frequency was 51.6% (95% CI: 42.1-61.1), the pooled serious nocebo response and drop-out frequency due to nocebo were 2.3% (95%CI: 1.2 -3.4) and 0.7% (95%CI: 0.1 -1.3).
Conclusions:
Placebo responses in anti-CGRP monoclonal trials are average and comparable to those seen in topiramate trials. Nocebo responses in trials of anti-CGRP monoclonals for EM, were average or low, compared to treatments of other neurological disorders and were lower than those seen in topiramate trials for EM. Nocebo responses in trials of anti-CGRP monoclonals in CM, were average or low and comparable to those seen in onabotulinum toxin A trials for CM.
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Functional connectivity and photo-, phono-, osmophobia in migraine Noboru Imai 1 , Asami Moriya 1 , Eiji Kitamura
Background: Migraine attacks are typically associated with photo-, phono-, or osmophobia. To explore the aforementioned 3 conditions in migraine development, we investigated differences in whole brain resting-state functional connectivity (FC) between patients with and without these conditions. Methods: Sixty-two women with migraine underwent resting-state functional magnetic resonance imaging during the interictal phase. We compared resting-state FC between subjects with and without photo-, phono-, or osmophobia using region of interest to region of interest analysis of 91 cortical, 15 subcortical, and 26 cerebellar areas. Results: The patients with photophobia showed a higher connectivity between the vermis 9 (ver9) and bilateral (bil) intracalcarine cortex (IC)/bil cuneal cortex (cuneal)/bil lingual gyrus (LG)/bil supracalcarine cortex, as well as the right (r) cerebellum (cereb) 4-6 between the r cuneal and left (l) amygdala/l accumbens/r paracingulate gyrus. Photophobia patients also demonstrated higher connectivity between the l cuneal and l amygdala, as well as a lower connectivity between the ver9 and l angular gyrus than did patients without photophobia. The patients with phonophobia demonstrated a higher connectivity between the l cereb8-9 and bil cereb6/r temporal occipital fusiform cortex (TOFusC), between the ver9 and bil cereb6/l TOFusC/l inferior temporal gyrus/l superior temporal gyrus, between the r IC and l supramarginal gyrus, and between the l amygdala and l parahippocampal gyrus, as well as a lower connectivity between the cereb7-8 and r middle frontal gyrus/r aTOFusC than did patients without phonophobia. Finally, the patients with osmophobia demonstrated a higher connectivity between r cereb6 and the brainstem than did those without osmophobia. Discussion: Our results suggest that the cerebellum plays a key role in the relationship between photo-, phono-, and/or osmophobia and neural FC, particularly in migraine development. 
Background
The discovery of anti-calcitonin gene-related peptide (anti-CGRP) and its connection to migraine, led to the development of diseasespecific drugs. The four novel anti-CGRP monoclonal antibodies (mAb) have been investigated in a large Phase II-III clinical programme, showing similar efficacy to the currently used drugs for migraine prevention but a lot of skepticism exists regarding their adverse events. Methods Literature searches were conducted on MEDLINE (PubMed), Scopus, and clinicaltrials.gov, using several key words and their combinations. Search terms included: migraine, anti-calcitonin generelated peptide monoclonal antibodies, adverse events. References from the selected articles were also thoroughly screened for other pertinent articles. During the screening of the abstracts/full texts, the publications that were not relevant to this review were removed.
Results
The most common adverse events that have been reported more frequently in the active anti-CGRP mAb arms versus placebo arms are injection-site pain, erythema, upper respiratory infection, nasopharyngitis, fatigue, influenza, joint pain, back pain and headache.
The main concern regarding their use was related to the potential cardiovascular effects and liver toxicity. Existing data do not confirm any cardiovascular effect. No interactions with other preventative drugs have been reported, as mAb elimination is mainly the result of proteolysis and does not involve metabolism by liver enzymes, making drug-drug interactions and hepatotoxicity unlikely. Discussion To date, the overall safety profile of anti-CGRP mAb for the prevention of migraine has been reported to be more than satisfactory. Safety questions were raised due to preclinical data from studying and blocking CGRP, but no safety flags occurred during development. Long-term Phase IV trials are needed to further evaluate the safety of anti-CGRP mAb.
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A real-world analysis of the burden of migraine in patients with prior treatment failures: evidence from the BECOME study METHODS BECOME was a prospective, multicentre, non-interventional study in adult patients with migraine, conducted in two concurrent parts over 3 months across Europe and Israel. Part 1 assessed the characteristics of all migraine patients visiting headache specialist centres over a 3-month prospective period, including frequency of PPTF (results presented separately). Part 2 of the study examined burden of disease using patient-reported outcome questionnaires ( Table 1) in visiting migraine patients with ≥1 PPTF and ≥4 MMD, identified by study investigators during Part 1. RESULTS Overall, 20,837 patients were screened in Part 1; 2419 were included in the Part 2 analysis. The mean±SD age of patients in Part 2 was 43.0±11.56 years; the majority were female (86.9%) and diagnosed with migraine without aura (53.4%). Overall, Part 2 patients reported a EuroQol visual analogue scale (VAS) score of 67.3±20.36, severe impact (HIT-6 score 65.2± 5.59), and severe disability (MIDAS disability grade IV, 81.9% of patients) due to headache ( Table 1 ). The burden of disease generally increased in line with increases in PPTF and MMD ( Table 2) . DISCUSSION BECOME confirms the significant burden of disease among migraine patients who have failed prior prophylactic treatments and provides real-world evidence of the continuous need for improved treatment of patients with difficult-to-treat migraine. BACKGROUND AND AIMS Real-world evidence on the characteristics of patients with migraine from Europe is limited. The current study provides real-world evidence on the characteristics of patients visiting European headache specialist centres. METHODS BECOME was a prospective, multicentre, non-interventional study in adult patients (18-65 years) with migraine consisting of two parts, conducted across Europe and Israel. In Part 1, all patients visiting the participating headache specialist centres over a 3-month prospective period were screened for frequency of prior prophylactic treatment failures (PPTF), monthly migraine days (MMD), and other characteristics ( Table 1) . Patients identified by study investigators with ≥1 PPTF and ≥4 MMD were enrolled in Part 2 of the study, which examined the burden of disease and healthcare resource utilisation (results presented separately).
RESULTS
Of the 163 centres participating in the study, 156 had data available for Part 1. As shown in Table 1 , 20,837 patients with migraine visited the headache centres during screening period, of which 62.2% reported ≥1 PPTF and 74.3% reported ≥4 MMD. Furthermore, 16.9% of patients reported ≥4 PPTF and 22.9% reported ≥15 headache days with ≥8 MMD. Approximately a quarter (27.0%) of patients with migraine visited the centres for the first time.
DISCUSSION
The BECOME study represents real-world characteristics of the migraine patient population visiting headache specialist centres in Europe and Israel. Nearly 17% of the study population reported ≥4 prior prophylactic treatment failures and more than 20% reported ≥15 headache days per month, demonstrating the high burden of disease, and a high unmet need with current prophylactic migraine therapy. Main objective: There are restricted evidence based data about the chronification of migraine in the natural course of the disease. The main objective of this study was to determine the factors affecting the chronicity of patients with episodic migraine in patients undergoing headache outpatient process. Patients and Methods: This study is conducted as a part of Turkish Headache Database Project. 3629 migraine patients registered in database, between 2000-2017. Among these, 2042 of these patients were diagnosed as episodic migraine and 1227 had chronic migraine at first visit. 68 patients undergoing follow-up at least two visits, transformed chronic migraine and compared to others. Demographic, clinic, phenotypic, epigenetic factors were compared between chronics and other patients. Statistical analysis was performed accordingly. Results: The results showed there is a statistically significant relationship between chronicity and vertigo (p=0.007), cranial autonomic symptoms (p=0.037) and allergy (p=0.026). Co morbidity of allergy in migraine patients with chronic is 7.624 times higher than the episodic migraines. In addition, osmophobia (p=0.017), comorbid concomitant Diabetis Mellitus (p=0.016), coronary artery disease (p=0.025) and headache triggered by hunger (p=0.001) were observed to be more prevalent in episodic migraine.
Conclusion:
The study results showed that the presence of vertigo, cranial autonomic symptoms, concomitant allergy were effective in the chronicity of migraine with requires much more attention to migraine comorbidities associated rather than diagnostic peculiarities, not only for diagnosis but also for defining coping options. Table 1 . On all efficacy outcomes assessed, patients on continuous erenumab showed sustained efficacy, while those who initiated erenumab in the OLEP showed sustained improvement from Week 13 onwards. Nearly 80.8% (overall group), 76.3% (continuing erenumab) and 85.2% (initiating erenumab) of patients reported adverse events (AEs). The corresponding incidences for serious AEs were 6.7%, 5.9%, and 7.4%. No deaths were reported. Discussion Efficacy of erenumab was sustained throughout 64 weeks in a difficultto-treat patient population with multiple prior preventive treatment failures in both continuous erenumab and those initiating erenumab treatment groups. Safety of erenumab was in line with previously reported clinical trials. Background Typical aura without headache (TAH) presents either as an isolated symptom in 4% of migraineurs or may occur typically later in life in 38% of migraineurs with headache. TAH describes typical aura neither accompanied nor followed by headache. Methods We present a case series of 5 patients with isolated TAH. Results Case 1: A 66-year-old man 8 years ago experienced recurrent visual episodes with gray waves from the periphery to the center bilaterally for 5-15min. Clinical and diagnostic work-up were unremarkable. Case 2: A 34-year-old woman from a decade ago had recurrent episodes of blurred vision with flashes of light bilaterally, started peripherally and gradually progressed centrally for 15-30min. Clinical and diagnostic investigation were normal. Case 3: A 37-year-old woman 7 years ago described episodes of visual blurring with small bright dots and flashes of light, often colorful, centrally that gradually progressed peripherally either in the left or in the right eye for 20-30min. Also, 2 years ago she had an episode with Change from the DBTP baseline in MPFID-EA −6.6 (7.7) −5.1 (9.4) −5.9 (8.6) 
A22
A25
The relationship between primary headaches and thyroid disorders: A retrospective study from a Greek Headache Outpatient Clinic Spanou Ioanna, Christidi Foteini, Liakakis Georgios, Rizonaki Konstantina, Bougea Anastasia, Anagnostou Evangelos, Kararizou Evangelia Background Primary headaches and thyroid disorders constitute common medical conditions; with a prevalence of 15% for migraine, 38% for tension-type headache (TTH), and 0.2% -5.3% for clinical hypothyroidism. To date, numerous studies suggested a bidirectional relationship between migraine and hypothyroidism, though certain had contradictory results. Methods We retrospectively evaluated the clinical records of 427 patients referred to the Headache Outpatient Clinic of Eginition Hospital from 2010 to 2018 and diagnosed with a primary headache. Thyroid dysfunction was assessed mostly based on patients' self-reports. Results Out of 427 patients (Male/Female = 76 / 351), 253 patients (59.3%) were diagnosed with migraine without aura, 53 (12.4%) with TTH, 49 (11.5%) with migraine with aura, 29 (6.8%) with medication-overuse headache, 23 (5.4%) with mixed-type headache (migraine with/without aura and TTH), 9 (2.1%) with cluster headache, and 11 (2.6%) with other type of primary headache. The prevalence of any type of thyroid disorder was 20.8% (89/427 patients). In the total sample, 27 patients (6.3%) reported hypothyroidism, 12 (2.8%) Hashimoto's thyroiditis, 3 (0.7%) hyperthyroidism, 18 (4.2%) unspecified thyroidopathy, 14 (3.3%) thyroid nodules, 3 (0.7%) thyroid goiter, and 12 (2.8%) thyroidectomy. Further statistical analysis between categorical variables (χ 2 ) did not reveal any significant association (p>0.05) between headache subtypes and thyroid dysfunction, including specific categories. Discussion Thyroid disorder is frequent among primary headache patients. Although we did not find any specific association between headache subtypes and specific thyroid disorder, the high prevalence of thyroid dysfunction in general (20.7%) and specifically hypothyroidism (6.3%), needs further clarification in prospective longitudinal studies, highlights the importance of a multidisciplinary approach and might has significant clinical implications for patients' treatment. Background Nearly 1.7 million traumatic brain injuries (TBI) occur every year in the United States of America. Headache is the most common complaint, and it can occur after mild, moderate, or severe injury. Several researchers have reported that post-traumatic headache is more common after mild TBI than after severe TBI -in patients who sustained a loss of consciousness. However, International Classification of Headache Disorders diagnostic criteria for posttraumatic headache attributed to mild head injury does not distinguish between loss of consciousness and no loss of consciousness, but rather include both "no loss of consciousness," and "a loss of consciousness of < 30 minutes." The purpose of this study was to determine if there was an association between loss of consciousness (regardless of duration) and the development of chronic posttraumatic headache. Methods A retrospective chart review was undertaken of new patients at a tertiary headache center with the diagnosis of chronic post-traumatic headache from 2013-2018. Physician documentation was examined for loss of consciousness at the time of the trauma. If the physician did not document loss of consciousness or maintenance of consciousness the patient was not included in this study. Results A total of 180 patient charts contained documentation regarding consciousness at the time of the trauma. Loss of consciousness was reported in 68 cases, and no loss of consciousness was reported in 112 patients. We ran a Chi Square of the data using The Statistical Package for the Social Sciences to determine the asymptotic significance of 0.001. This result suggests that there is only a 0.1% chance of no relationship between loss of consciousness and chronic post-traumatic headache. Discussion In our study of patients with chronic post-traumatic headache, 62% of the patients did not lose consciousness during and after trauma compared with 38% who lost consciousness at the time of the trauma. There is an association between loss of consciousness and the development of chronic post-traumatic headache. In our study patients were more likely to develop chronic post-traumatic headache if there was no loss consciousness at the time of the trauma. This is consistent with most of the current literature that suggests mild TBI leads to post-traumatic headache more often than severe TBI. Given that mild TBI includes both "no loss of consciousness" and "loss of consciousness of < 30 minutes," however, we believe that our research is novel because of the distinction between loss of consciousness and no loss of consciousness. This suggests that no loss of consciousness may be a risk factor for the development of chronic post-traumatic headache. It is likely that other factors, such as anxiety or depression, may represent even greater risk for the development of this condition. Areas for future research include assessing the association of anxiety or depression, together with or without loss of consciousness and the development of chronic post-traumatic headache. 
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Background
The biological mechanisms of the progression of migraine from episodic to chronic are poorly understood. Medication overuse (MO) is considered by many as one of the main determinants of migraine progression. Recently, in a preliminary study, we have shown alterations of anandamide metabolism in circulating peripheral blood mononuclear cells (PBMCs) of migraineurs with a gradient of gravity from the episodic to the chronic type. In this study we further investigated the asset of the endocannabinoid system (ES) in migraine as a function of disease severity. Methods Using rt-PCR we essayed the gene expression of the enzymes involved in the metabolism of 2-Arachidonoylglycerol (2-AG), sn-1-specific diacylglycerol lipase (DAGL) for the synthesis and monoacylglycerol lipase (MAGL) for the degradation, in the PBMCs of 21 subjects with episodic migraine (EM), 19 subjects with chronic migraine and MO (CM-MO) and an age-and sex-matched control group (CT, N=21). Subjects in CM-MO group were tested at baseline and 2 months after detoxification.
Results
The levels of MAGL mRNA were significantly higher both in the EM and CM-MO groups as compared with CT. DAGL gene expression was increased in CM-MO group at baseline and it decreased following detoxification, when it reached mRNA levels comparable to the EM group. Discussion These findings confirm the involvement of ES in migraine disease showing that not only anandamide, but also 2-AG metabolism is altered. In the case of CM-MO, our data point to an increased turnover of this latter endocannabinoid, a condition that is partially reverted by detoxification. Authors declare no conflicts of interest. Method: The clinical symptoms of 11 HM consecutive patients who visited the tertiary headache center in Japan were analyzed retrospectively. Results: Of the 11 HM cases, 10 were sporadic HM (SHM), and 1 was familial HM (FHM). The patients were 13 to 67 years of age (average 36.2 years), including 7 males and 4 females. Headache was bilateral in 4 cases, unilateral side variable in 4 cases, and strictly unilateral in 2 cases. One case had no headache. The maximum headache intensity was NRS 9.7/10 on average. The longest headache duration was 39.6 h on average, with a maximum of 5 days. The four cases had allodynia. Aura symptoms preceded headache in two cases, aura and headache at the same time in two cases, and headache before aura in six cases. The motor symptoms were unilateral in nine cases and bilateral in two cases. Out of six cases of unilateral headache, ipsilateral headache was noted in four cases and contralateral headache in two cases. The progress of paralysis was the upper limbs followed by the lower limbs in four cases, at the same time in two cases, and the lower limbs followed by the upper limbs in two cases. The duration of paralysis was from 5 minutes to 2 months, with a median of 150 minutes, and in 2 cases, the paralysis was persistent. Sensory symptoms appeared in all cases. Speech symptoms were confirmed in eight cases and visual symptoms in seven cases. Brainstem symptoms were observed in eight cases, two of which showed a decreased level of consciousness. The order of occurrence of each aura was two cases along the order of visual sense, sensation, language, exercise, brain stem, but most of them were not constant. Genetic testing was performed in 10 cases, and SCN 1 A and ATP 1 A 2 were detected in 1 SHM case each. Discussion: Many SHM cases are encountered at the tertiary headache center, some of which have persistent motor symptoms. The order of aura symptoms is diverse, with headache often preceding, and paralysis may be bilateral and ipsilateral. Given that some cases do not meet the diagnostic criteria, genetic testing is useful for confirming the diagnosis. BACKGROUND: We present a network meta-analysis (NMA) of fremanezumab and erenumab for reduction in monthly migraine days (MMDs) in patients with episodic migraine (EM) who failed 2-4 prior treatments. METHODS: RCTs of fremanezumab and erenumab were identified via a systematic literature review using MEDLINE, Embase, Cochrane Library, and Health Technology Assessment documents. All trials were published post 2007, and included adults with EM (<15 headache days per month) who had failed 2-4 prior preventive migraine treatments due to efficacy, safety, or tolerability. Reductions in MMDs during weeks 1-4 and weeks 1-12 were compared using pairwise treatment differences and 95% credible intervals (CrIs) obtained from Bayesian NMAs. RESULTS: Two trials were included for reduction in MMDs at weeks 1-4 and 1-12 among EM patients. BACKGROUND: We present a network meta-analysis (NMA) of responder rates (RR) of CGRP monoclonal antibodies and other common treatments in migraine patients with ≥3 prior treatment failures. METHODS: A systematic literature review of MEDLINE, Embase, Cochrane Library, and Health Technology Assessment documents was conducted to identify randomized clinical trials of fremanezumab, erenumab, and onabotulinumtoxinA (onaA) (2007-present). Adults with episodic (EM) or chronic migraine (CM) and ≥3 prior treatment failures were included. 30% RR in CM and 50% RR in EM were compared at the end of treatment period (weeks 9-12 or 21-24) between treatments using pairwise odds ratios (ORs) and 95% credible intervals (CrIs) from Bayesian NMAs. RESULTS: In CM patients, two trials evaluated 30% RR. Compared to placebo, improvements in 30% RR were significant for fremanezumab monthly 675/225/225 mg 
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The effect of consulting a specially trained headache nurse on the quality of life of headache patients: controlled prospective interventional study Kristi Tamela Background. Chronic headaches are difficult to treat, better management strategies and more efficient preventative care are needed. The goal of this study was to describe how consulting a specially trained headache nurse affects the quality of life (QoL) of headache patients. Methods. Data was prospectively collected over the course of 2 years. The trial included patients of both genders (ages 18-65 years) with a diagnosis of a primary headache and no other significant comorbidity which could affect the QoL of the individual whom a neurologist had referred to a headache nurse consultation. Participants were randomly assigned to three groups. The first group received three consultations during the six month period: at the start of the trial and after three and six months. The second group was evaluated three times but the consultations took place twice: three and six months after the initial appointment. The control group was evaluated twice -first during the initial appointment and the second six months later; they received one consultation session at the end of the trial. Two tests were used for evaluation: Headache Impact Test (HIT-6) and Headache Under-Response to Treatment (HURT) survey. The study was approved by the Research Ethics Committee of the University of Tartu. Results. The trial included 80 patients; 64 of them attended all study appointments. The results of the study indicated that the QoL of patients who consulted a nurse improved remarkably compared to the control group. HIT-6 and HURT scores indicated substantial changes (p<0.01) in the mean scores of the first and second group. In the first group, the mean score of HIT-6 decreased from 63.3 to 56 at the time of the last appointment and the mean HURT score fell from 13.5 to 6.9. The second group scores dropped from 63 to 57 and from 13.5 to 7.1 respectively. The control group's mean scores of HIT-6 and HURT changed insignificantly. Discussion Consulting a headache nurse improves patients' QoL. The effect becomes apparent over a longer period of time. The results do not allow to conclude that a first consultation immediately after a doctor's appointment would be better for the QoL outcomes compared to a first consultation that took place three months after the initial appointment. Methods:Descriptive retrospective single-center study with a prospectively collected database, including CCH patients treated with BTX-A according to the PREEMPT study protocol or modified unilateral PREEMPT protocol,repeated every three to four months. Simultaneous preventive medication was initially continued,being three patients carriers of occipital neurostimulators. Primary endpoints are effectiveness(measured as at least a 50% reduction in attack frequency or pain intensity compared to baseline) and reduction in disability(measured by HIT6 and HADS scores).Data obtained from diaries and medical registries. Results:19 patients were included,15 males,age range 29-76 years(-mean 46.94(+/-11.63SD) and disease duration of 10.28 years(+/-9.42SD). Mean number of BTX-A dosis injected were 3(range 1-6) in an average follow-up time of 11.84(+6.74SD)months. Effectiveness in attack frequency and pain intensity was observed in 47.37% and 52.63% patients respectively. Improvement in disability scores was observed in 7 out of 11 patients. 26.32% patients achieved a reduction in the number of preventive medication.No adverse events were recorded. Discussion:Our data show promising results regarding BTX-A treatment in CCH, not only in reducing the frequency or intensity of attacks, but also in improving quality of life. We highlight the sample size of our population.A more extensive follow-up time and experience are needed to establish which protocol may have better outcomes and whether patient characteristics predict response to BTX-A. Background: Botulinum toxin type A(BTX-A) is one of the most potent neurotoxins, has been shown to be a choice of treatment for trigeminal neuralgia (TN), and may be an efficient, safe and novel strategy. Methods: Prospective descriptive study. We included 16 patients with TN without response to 2 oral preventive treatments (OPT).The BTX-A administration protocol was: branches V2-V3, 25 IU/0.5 ml, distributed in 10 points for each branch and 3 contralateral points. Branche V1, according to the bilateral PREEMPT protocol, administered every 3 months. The main objective was to assess the effectiveness:50% reduction in the intensity according to the visual analogic scale (EVAS) and/or the 50% reduction in the frequency of the crisis. The secondary objectives were the tolerance and safety, the reduction OPT and disability scales (HitT-6 and the scale of anxiety and depression (ADH)). Results: 16 patients were included,7 males(43.8%),age range 40-86 years(mean 62.4 ±14.6SD). Mean follow-up time:73 months (IQR of 19-363 months); mean number of Botox doses was 3 (range 1-7,IQR 2). Had been treated with a median of 4 OPT (range 2-5). The proportion of intensity responders was 81.25% and 62,7% of frequency responders.4 patients (25%) discontinued the study. Median number of preventive drugs was reduced to 3 (range 0-4). In the disability scales, the average reduction was: 8.21(SD ± 12.2) for HIT-6 scale, 3.57(SD ± 5.0)for ADH-anxiety and 2.64 (SD ± 4.2) points for ADHdepression . Discussion: The administration of BTX-A for trigeminal neuralgia is effective, and associated with a reduction in number of preventive drug and in disability scales (Hit-6 and ADH).Adverse effects are frequent(43.8%)but not incapacitating. 
METHODS:
The study included 53 patients with mean age of 10.67 ± 3.1 (24.5% M and 75.5% F). All patients had a diagnosis of migraine without aura (ICHD 3 criteria) and received umPEA (600 mg/day orally) for three months. We compared the attack frequency (AF) and attack intensity at baseline and after three months. Patients were asked to classify the intensity of the attack with a value ranging from 1 to 3 where 1 means mild attack, 2 moderate and 3 severe attack. RESULTS: After 3 months of treatment with um-PEA, the headache frequency was reduced by >50 % per month in 56.6% patients. Three patients discontinued treatment too early (less than a month) and were not considered in the results. After three months of treatment the number of monthly attacks decreased significantly compared to the start of therapy (from 13.89 ± 7.6 SD to 6.43 ± 5.1 SD; p<0.05) The intensity of the attacks went from 1.70 ± 0.6 (pre-PEA) to 1.19 ± 0.5 (post-PEA). DISCUSSION: Our preliminary data show that um-PEA administered for three month reduces pain intensity and the number of attacks per month in in pediatric patients with migraine. Although the small number of patients and the lack of control group do not allow us to consider these initial results as definitely reliable, they encourage us to expand the sample. Background : Supraorbital neuralgia is a rare disorder characterized by unilateral pain involving the supraorbital region meeting the following diagnostic criteria set by the International Headache Society Classification (ICHD-II): A) forehead pain in the territory supplied by the supraorbital nerve, without side shift; B) tenderness on either the supraorbital notch or traject of the nerve; and C) absolute, but transitory relief of symptoms upon supraorbital nerve blockade. Case study: A 51-year-old male with a 5-year history of severe stabbing intermittent pain in the right frontal region referred to our department because of increasing frequency and intensity of the pain over the last few months. The symptoms usually emerged during exposure to cold wind while recently appeared even with light touch being quite disabling for the patient. There was no past history of trauma but he used to wear a tight-fitting motorcycle helmet. On palpation, there was a tender area over the exit of the right supraorbital nerve. Neurological assessment and brain imaging was normal. The patient was advised to change his helmet and to receive pregabalin to a total dose of 150mg. The patient improved significantly and after a 6-month-period, he gradually discontinued the medication without recurrence. Discussion: Our patient fulfilled the criteria A and B set by ICHD-II for supraorbital neuralgia. He also exhibited allodynia and exteroceptive precipitating mechanisms usually seen in cases related to head trauma, although he did not reported any. Due to the rarity of the condition and its similarity of presentation as other headaches, it is important to correctly diagnose and treat the patient. Pregabalin should be considered as a possible treatment for supraorbital neuralgia other than supraorbital nerve block. Written, informed consent for publication was obtained from the patient. Background. Periodic migraine variants are a group of disorders affecting patients with migraine or with an increased risk of presenting it, and likely represents an early life expression of migraine. Cyclic vomiting syndrome (CVS) and benign paroxysmal torticollis (BPT) are well characterized and represent a frequent cause of request for specialistic consultations. Aim of this study is to longitudinally assess the rate of headache in patients presenting with CVS and BPT during infancy, and to define the main clinical features of the disorder. Methods. We administered a questionnaire to the parents of all our pediatric patients with previous diagnosis of CVS and/or BPT according to ICHD-3; questions were focused on the main clinical features of the disorder as well as the prognosis, with particular emphasis on the development of headache. Results. For the final analysis we considered 82 patients with CVS and 33 with BPT. Seventy-nine percent of patients with CVS presented with headache during the follow-up, with a mean age at onset of 6 years; 67% of patients with BPT suffered from headache during the follow-up, with a mean age at onset of 5 years. Discussion. CVS and BPT are associated with a very high risk of developing headache, mostly migraine, later in life. In both groups of patients, the vast majority presented with different periodic migraine variants at different ages, thus suggesting an age dependent evolution of migraine-like symptoms before the onset of clear migrainous headache. Background: VIP, CRGP, and PACAP have important roles in migraine pathogenesis but their diagnostic value is controversial. Objective: To determine and compare these neuropeptides serum levels in a cohort of chronic migraine (CM), episodic migraine (EM), and healthy controls (HC). Methods: Peripheral blood samples from 304 age and sex matched subjects (28 males and 276 females: 108 CM, 98 EM and 98 HC) were drawn, centrifuged, and stored at -80º C. ELISA-based assays were performed using BlueGene Biotech Co kit for PACAP and CloudClone Corp kit for CGRP and VIP. Standardized values were compared using t-test for univariate analysis. A multinomial regression analysis was performed to identify predictors of clinical diagnosis. Pearson's "r" statistic was used for bivariate correlation analysis and Chi2 for categorical variables. Area under the curve (AUC) in ROC curves were used to assess their diagnostic value. Results: VIP, PACAP and CGRP were increased in CM vs EM and HC (p<0,001), but not in EM vs HC. Age inversely correlated with PACAP and CGRP but not with VIP. Significant correlation occurred between VIP and PACAP (r=0.347), VIP and CGRP (r=0.526), and PACAP and CGRP (r=0.504). Only VIP (B=0.009) and PACAP (B= 003) predicted the clinical diagnosis for CM, but not EM. GCRP did not predict CM nor EM. Only 60.2% of CM, 68.8% of EM, and 15.5% of HC were correctly predicted. AUC were significant for VIP and PACAP (0.703± 0.33, 0.739±0.32, respectively). Both had low sensibility for CM (0.53 and 0.50 respectively), and better specificity (0.83 and 0.939 respectively). Conclusion: We found that VIP, CGRP and PACAP were significantly increased in CM. In the present study CGRP value as a CM biomarker was relatively low. Standardized techniques for analyzing these neuropeptides are strikingly needed. Funded by ISCIII-FISS PI15/ 01285 and IDIVAL. Abstract: Introduction: Diet is recognized as a possible potential factor in migraine pathogenesis. As fruits and vegetables are considered as major sources of vitamins, minerals and dietary antioxidant, numerous studies have suggested them effective in various types of chronic disease. Limited evidence exists on the effect of diet on pediatric migraine, so we aimed to investigate the association between fruit and vegetable consumption and odds of migraine in children Method: We conducted a case-control study in tertiary hospital, Tehran, Iran. One hundred children with migraine as case group and 190 sex-matched healthy controls were recruited in this study. Definite diagnosis of migraine was based on 2018 international classification of headache disorder 3 (ICHD3) criteria and confirmed by a neurologist. Demographic and anthropometric characteristics were collected. Common dietary intake of participants was obtained using a validated semi-quantitative food frequency questionnaire (FFQ). In order to run logistic regression models, all variables were classified into tertiles except for dietary fiber which was stratified into quartiles. Result: Children in the migraine group had significantly higher BMI and age compared with the control group (P-value=0.00). After adjustment for age, gender, BMI and total energy intake a significant association between higher intake of vegetables in second tertile (OR: 0.47;CI:0.24-0.92), fruits in third tertile (OR: 0.31;CI:0.14-0.69) and fiber in fourth quartile (OR: 0.28;CI:0.095-0.85) was obtained. By controlling for all confounders in model 3, the odds of migraine, decreased by 50% and 70% by increasing in vegetables and fruits consumption, in the second tertile of vegetables (P-value=0.04) and the third tertile of fruits (P-value=0.00). We noticed 50% and 70% reduction in odds of assigning to migraine group by increasing the consumption of vegetable and fruit to 218/5 gr/week and 578/85 gr/ week in the second tertile of vegetable and third teritle of fruit compared with the first tertile, respectively. Also a 72% reduction in Introduction Excessive daytime sleepiness (EDS) is defined as 'sleepiness in a situation when an individual would be expected to be awake and alert' and has been reported to be associated with several neurological disorders including headache disorders. Tension-type headache (TTH) is the most common headache disorder in general population. Owing to its higher prevalence, the social burden of TTH is greater than that caused by migraine. Previous study has demonstrated that EDS was prevalent among migraineurs and was associated with an exacerbation of migraine. Nevertheless, information on the association between EDS and TTH is limited. The aim of this study is to investigate the association and impact of EDS on participants with TTH in a population-based setting. Methods This study used the data of the Korean Headache-Sleep Study (KHSS), which was a population-based survey regarding headache and sleep for Korean adults aged 19-69 years. If the score on the Epworth Sleepiness Scale (ESS) was more than or equal to 11, the participant was classified as having EDS. Results Of the 2695 participants, 570 (21.2%) and 313 (11.6%) were classified as having TTH and EDS, respectively. EDS was more prevalent among TTH participants with ≥15 headache frequency per month compared with participants with non-headache (35.7% vs. 9.4%, p < 0.001). Prevalence of EDS among TTH participants with headache frequency <1 per month (8.3%, p = 0.511) and TTH participants with headache frequency 1-14 per month (13.5%, p = 0.054) was not significantly different from that of those with non-headache. TTH participants with EDS had higher headache frequency per month (4.3 ± 8.1 vs. 1.7 ± 4.2, p = 0.013), Visual Analogue Scale for headache intensity (5.0 [3.0 -6.0] vs. 4.0 [3.0 -6.0], p = 0.008), Headache Impact Test-6 score (47.1 ± 7.3 vs. 43.5 ± 7.6, p < 0.001) and more depression (Patient Health questionnaire score≥10) (12.7% vs. 3.2%, p < 0.001) compared to those without EDS. Multivariable logistic regression revealed that headache frequency (β=0.051, p=0.016), Headache Impact Test-6 score (β=0.051, p=0.016), and depression (β=1.230, p=0.011) were independently associated with the existence of EDS among TTH participants. ConclusionsEDS is more prevalent in TTH participants with >15 headache frequency per month compared to those with nonheadache. TTH participants with EDS was independently associated with higher headache frequency, increased impact of headache and higher prevalence of depression compared to those without EDS. Βackground Hemiplegic migraine (HM) is a rare and complex clinical entity which is characterized by aura consisting of fully reversible motor weakness as well as visual, sensory and/or speech/language symptoms and is categorized as familial (FHM) when at least one first-or seconddegree relative experiences attacks of HM. In some cases, genes that prove causality have been identified (CACNA1A, ATP1A2, SCN1A). Although patients with mutations in CACNA1A may present with cerebellar ataxia, the presence of both clinical entities and moreover the emergence of late-onset cerebellar symptoms in a patient with known FHM, is extremely rare.
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Case report
We present a case of 32-year-old man with a long-standing diagnosis of sporadic HM treated successfully with valproic acid who reports a mild difficulty in walking and a slight change in his speech, starting from 2 years ago. Neurological examination revealed cerebellar signs of mild dysarthria/scanning speech, mild gait ataxia (difficulty in tandem walking test), and dysdiadochokinesia while neuroimaging studies revealed cerebellar atrophy. The rest laboratory testing was without any pathological finding.
Results
The following genetic tests for mutations in spinocerebellar ataxia related genes (SCA panel) were all negative. Finally, a genetic study of FHM was performed and a heterozygous point mutation in CACN A1 gene (c.4046G>A, pArg1349Gln) was revealed, supporting the above findings. Discussion Whereas changes in ion channels may provide an explanation for aura symptoms (cortical hyperexcitability) and cerebellar degeneration (Purkinje cell expression), the pathophysiology and clinical presentation of CANCA1A mutations remain unknown. It is proposed that in any newly diagnosed case of HM, especially when cerebellar signs are present, appropriate genetic testing should be performed even in the absence of positive family history. Written, informed consent for publication was obtained from the patient. Background: Up to 90% of postural tachycardia syndrome (PoTS) patients report frequent, problematic headaches. According to current diagnostic criteria for PoTS, associated headaches might be expected to be strictly orthostatic, though comorbid migraine headache is common. Given this observation, it is possible that the two disorders interact pathophysiologically. Methods: 30 PoTS, 30 chronic migraine (CM), and 30 non-headache (NH) control subjects completed a migraine questionnaire, MIDAS/ HIT6, and sensory/autonomic symptom assessment. Sensory testing included mechanical pain thresholds by von Frey Hair and quantitative light sensitivity thresholds. Results: Photophobia and allodynia symptom scores were significantly higher in both CM and PoTS groups compared to controls. COMPASS-31 autonomic symptom scores were significantly higher in PoTS compared to CM, but both groups had significantly
